Pfizer's Lyme Vaccine Shows Promise in Late-Stage Trials

0:00It's March 24, I'm Cory with the story, and this is Entertainment and Celebrity News today, your AI-powered entertainment report. Pfizer and partner Valneva just shared promising results from late-stage trials on their experimental Lyme disease vaccine. The shot, known as PF07307405, hit 73.2% efficacy and stopping confirmed cases after the fourth dose, beating out a placebo group. The trial saw fewer Lyme infections than planned, which meant it missed an initial target at first. Researchers dug back into the data and pulled out a statistically strong outcome that backs the vaccine's potential. Experts call the findings encouraging, especially with emergency room visits, for tick-bites hitting near-record highs across the U.S. this summer. Lyme comes from black-legged ticks and brings fever, fatigue, headaches, and a telltale rash plus risks to joints, heart, and nerves if ignored. No vaccine exists now in the U.S. after the last one got dropped in 2002 over week sales.

1:04This candidate mirrors that old version with small tweaks, and it's the furthest along among current efforts, other projects trail years behind. Pfizer plans to submit for FDA approval soon, which could revive protection just as tick- worries grow nationwide.